Article Text

  1. E. R. Swenson,
  2. R. Eveland
  1. VA Medical Center and University of Washington, Seattle


Erythropoietin (EPO) is a potent cytoprotective cytokine that has been shown to reduce acute ischemia-reperfusion (I/R) injury in the brain, spinal cord, heart, liver and kidney independent of its hematopoietic effects. Although it may have other mechanisms of action, up-regulation of endothelial nitric oxide synthase (eNOS) and NO production by the vascular endothelium appears to be important. We tested whether human recombinant EPO (rhEPO) would protect against acute lung I/R injury of 90 min left hilar clamping followed by 4 hr of reperfusion in anesthetized Sprague-Dawley rats. Three groups of 5 rats were studied: a) CONT- thoracotomy but no I/R injury, b) I/R injury, and c) I/R injury plus 24 hr pretreatment with 5000 units/kg rhEPO. Gas exchange, hemodynamics, exhaled nitric oxide, and serum LDH were measured before and after 4 hr of reperfusion. Changes in lung wet to dry weight ratio and broncho-alveolar lavage fluid (BAL) protein, neutrophils (PMN) and tumor necrosis factor (TNF) were assessed. (Table)

EPO increased exhaled NO before the I/R protocol by almost 4-fold; 1.6 vs. 6.3 parts per billion (P ≤ 0.01). These findings of roughly 50-90% reduction in a variety of injury parameters demonstrate that EPO is effective in limiting acute lung I/R injury and that it may do so by increasing NO production.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.